BI dives deeper into cancer immunotherapy with new acquisition – Danbury News Times
Danbury News Times |
BI dives deeper into cancer immunotherapy with new acquisition
Danbury News Times The pharmaceutical giant, which has its North American headquarters in Ridgefield, announced a collaboration and license agreement with OSE Immunotherapeutics to jointly develop OSE-172, an antibody that targets myeloid lineage cells. OSE-172 is in … |
